# Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

> **NCT07264010** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 87 (estimated)

## Conditions studied

- Acute Myeloid Leukaemia (AML)
- Measurable Residual Disease (MRD)

## Interventions

- **DRUG:** Sorafenib (SORA)
- **DRUG:** Venetoclax (VEN)

## Key facts

- **NCT ID:** NCT07264010
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2026-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 87 (ESTIMATED)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07264010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07264010, "Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07264010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*